Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2463 in indolent non-Hodgkin lymphoma
2023-509254-58-00Phase 2Authorised
- Sponsor
- Enterome
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 4
01
Overview
Phase 2, open-label trial of EO2463 in indolent lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (4 cohorts), sponsored by Enterome. Primary endpoints: Recommended phase 2 dose and safety confirmation, Overall response rate during EO2463 monotherapy and 1 more. Planned start May 2021; status: authorised.
02
Drugs
EO2463
03
Conditions
indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2023-509254-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509254-58-00.